S&P Futures
4,131.25-1.50(-0.04%)Dow Futures
33,539.00-31.00(-0.09%)Nasdaq Futures
13,970.00-5.75(-0.04%)
Achieve Life Sciences, Inc. (ACHV)
12.90 +2.18 (20.34%)
After hours: 6:43PM EDT
Chart Events
Performance Outlook
| Previous Close | 11.08 |
| Open | 11.09 |
| Bid | 9.90 x 1100 |
| Ask | 12.88 x 1200 |
| Day's Range | 10.63 - 11.25 |
| 52 Week Range | 6.20 - 18.26 |
| Volume | 75,163 |
| Avg. Volume | 297,316 |
| Market Cap | 65.927M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.42 |
| Earnings Date | May 12, 2021 - May 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.20 |
- ACCESSWIRE
Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction
Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 25, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced online publication of the results from the Phase 3 RAUORA trial in the scientific journal Addiction.
- Zacks Small Cap Research
ACHV: Fourth Quarter and Full Year 2020 Results
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Fourth Quarter and Fiscal Year 2020 Results Achieve Life Sciences, Inc. (NASDAQ: ACHV) reported fourth quarter and fiscal year 2020 results in a press release and conference call held after market close on March 12, 2021. The company concurrently filed its 10-K with the SEC. Highlights from 2020 include the
- ACCESSWIRE
Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 16, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Achieve's Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M-Vest and Maxim Group.
